ÿþ<HTML><HEAD><TITLE>XI International Meeting on Paracoccidioidomycosis</TITLE><link rel=STYLESHEET type=text/css href=css.css></HEAD><BODY aLink=#ff0000 bgColor=#FFFFFF leftMargin=0 link=#000000 text=#000000 topMargin=0 vLink=#000000 marginheight=0 marginwidth=0><table align=center width=700 cellpadding=0 cellspacing=0><tr><td align=left bgcolor=#cccccc valign=top width=550><font face=arial size=2><strong><font face=Verdana, Arial, Helvetica, sans-serif size=3><font size=1>XI International Meeting on Paracoccidioidomycosis</font></font></strong><font face=Verdana size=1><b><br></b></font><font face=Verdana, Arial,Helvetica, sans-serif size=1><strong> </strong></font></font></td><td align=right bgcolor=#cccccc valign=top width=150><font face=arial size=2><strong><font face=Verdana, Arial, Helvetica, sans-serif size=1><font size=1>Resume:161-1</font></em></font></strong></font></td></tr><tr><td colspan=2><br><br><table align=center width=700><tr><td><b>Investigação</b><br><table width="100%"><tr><td width="60">161-1</td><td><b>The lung in treated Paracoccidioidomycosis patients: new insights into an old problem.</b></td></tr><tr><td valign=top>Authors:</td><td><u>Andre Nathan Costa </u> (HC-FMUSP - Pulmonary Division, Heart Institute (InCor), USP) ; Andre Luis Pereira Albuquerque (HC-FMUSP - Pulmonary Division, Heart Institute (InCor), USP) ; Adriana Satie Kono Magri (HC-FMUSP - Infectious Diseases Division, Hospital das Clínicas, USP) ; Gil Benard (HC-FMUSP - Laboratory of Dermatology and Immunodeficiencies) ; Ronaldo Adib Kairalla (HC-FMUSP - Pulmonary Division, Heart Institute (InCor), USP) ; Maria Shicanai Yasuda (HC-FMUSP - Infectious Diseases Division, Hospital das Clínicas, USP) ; Carlos Roberto Ribeiro Carvalho (HC-FMUSP - Pulmonary Division, Heart Institute (InCor), USP) </td></tr></table><p align=justify><b><font size=2>Abstract</font></b><p align=justify class=tres><font size=2>RATIONALE: Paracoccidioidomycosis (PCM) is the most frequent systemic mycosis in South America, and 80% of world cases occur in Brazil. Pulmonary involvement is the main feature in chronic form of disease, with some patients developing residual respiratory abnormalities after treatment. In this study we evaluated lung tomographic and functional abnormalities in PCM patients. METHODS: Prospective evaluation of 49 post-treatment lung PCM patients with chest high-resolution computed tomography (HRCT), spirometry, plethysmographic, cardiopulmonary exercise test, six minute walk test (6MWT) and respiratory quality of life questionnaire. RESULTS: Mean age was 57±7 years. Forty-nine patients were current or former smokers, mean length of 38.5±1.4 pack-years. Mean time elapsed between treatment institution and enrollment was 6±3.9 years, and mean treatment lengh was four years. Mean initial serology was 106±42 and mean final serology was 5±1. Main HRCT findings were architecture distortion (92%), septal thickening and reticular opacities (90%), bronchial wall thickening (84%), peribronchovascular interstitial thickening and nodules (64%) and ground glass opacities (48%). Air trapping was found in 78% of patients. The radiologic findings were diffusely present in all lung zones in 84% of patients. Pulmonary function tests showed: forced vital capacity 3.8±0.9L (93±18% predicted), forced expiratory volume in 1 second 2.5±0.7 L (79.6±20%), total lung capacity 6.2±1.3 L (101±16%), residual volume 2.5±0.9 L (125 ± 40%), and DLCO 72%. Cardiopulmonary exercise test showed: maximum oxygen uptake 21.0±1,2 mL/kg/min (66±17%), maximal work rate 73,0±9,2%, maximal heart rate 73,5±9,1%, oxygen pulse 10.9±2,8 mL/beat, minute ventilation 191.7±22.2 L/min (53.7±8,5%) and minute ventilation/maximal voluntary ventilation 0.61 ± 0.09, with a mean ventilatory reserve of 39%. Mean walked distance (6MWT) was 574±21 meters (85% of predicted). Saint George Respiratory Questionnaire mean values were 607±78 points, showing low impact of the pulmonary symptoms in quality of life. CONCLUSIONS: Herein we indicate, in disagreement with current literature, that adequately treated PCM patients present very frequent radiological abnormalities not solely attributed to tobacco exposure. However, these findings, associated to mild static and dynamic functional abnormalities and with slight abnormal exercise capacity, are not linked to a severe life impact.</font></p><br><b>Keyword: </b>&nbsp;LUNG, respiratory sequelae, treated paracocicdioidomycosis</td></tr></table></tr></td></table></body></html>